The original method of genomic sequencing took over a decade to complete. Now, next-generation sequencing can complete an entire human genome in a day. This
On October 6th, 2020, the NIH announced its awarded the third round of contracts to six new technologies for COVID-19 testing.
Organ-on-a-chip (OOAC) technology simulates human tissue on an electronic chip, aiding in the development and testing of new medicines, determining the toxicity of drugs and
Argonaut Manufacturing Services has completed its initiative to expand filling capabilities of Viral Transport Media (VTM) used for sample collection devices that test for COVID-19.
Point of care (POC) diagnostic devices produce results outside of laboratory settings by collecting and analyzing specimens at the time of the patient’s visit to
Medical devices help doctors and laboratories make diagnoses, administer medications, or provide assistance with daily living to patients with disabilities. While the patient is always
Scientific professionals understand that an idea for a new medical device launches a complex process of design, development, and prototyping. Medical device companies find that working with an experienced consultancy that specializes in refining ideas into finished products provides savings in cost and time.
Since 2004 Symbient has been at the forefront of diagnostic cartridge development resulting in over 300 disposable cartridges. As a product development firm, we specialize in plastic, disposable devices. Our success in this field is due to our expertise in highly complex “meso-scale” and microfluidic cartridges, production-quality prototype molding capabilities, and our production offerings for clinical studies. Clients receive end-to-end product development services.
Photo by CDC on Unsplash There is a race to fight the spread of Coronavirus, and Symbient is proud to be integral in the
Material Selection is a hot topic in the medical industry. So, please attend the panel discussion moderated by our Engineering Program Director, Stacie Depner. We’re